The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Open accessAbstract
Purpose: We investigated the antitumor effect of murine/human chimeric CD138-specific monoclonal antibody nBT062 conjugated with highly cytotoxic maytansinoid derivatives against multiple myeloma (MM) cells in vitro and in vivo. Experimental Design: We examined the growth inhibitory effect of BT062-SPDB-DM4, BT062-SMCC-DM1, and BT062-SPP-DM1 against MM cell lines and primary tumor cells from MM patients. We also examined in vivo activity of these agents in murine MM cell xenograft model of human and severe combined immunodeficient (SCID) mice bearing implant bone chips injected with human MM cells (SCID-hu model). Results: Anti-CD138 immunoconjugates significantly inhibited growth of MM cell lines and primary tumor cells from MM patients without cytotoxicity against peripheral blood mononuclear cells from healthy volunteers. In MM cells, they induced G2-M cell cycle arrest, followed by apoptosis associated with cleavage of caspase-3, caspase-8, caspase-9, and poly(ADP-ribose) polymerase. Nonconjugated nBT062 completely blocked cytotoxicity induced by nBT062-maytansinoid conjugate, confirming that specific binding is required for inducing cytotoxicity. Moreover, nBT062-maytansinoid conjugates blocked adhesion of MM cells to bone marrow stromal cells. The coculture of MM cells with bone marrow stromal cells protects against dexamethasone-induced death but had no effect on the cytotoxicity of immunoconjugates. Importantly, nBT062-SPDB-DM4 and nBT062-SPP-DM1 significantly inhibited MM tumor growth in vivo and prolonged host survival in both the xenograft mouse models of human MM and SCID-hu mouse model. Conclusion: These results provide the preclinical framework supporting evaluation of nBT062-maytansinoid derivatives in clinical trials to improve patient outcome in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Derksen, P. W. B., Keehnen, R. M. J., Evers, L. M., van Oers, M. H. J., Spaargaren, M., & Pals, S. T. (2002) · Blood · doi:10.1182/blood.v99.4.1405 · Cited by 274
Mahtouk, K., Cremer, F. W., Rème, T., Jourdan, M., Baudard, M., Moreaux, J., Requirand, G., Fiol, G., De Vos, J., Moos, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209699 · Cited by 105
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Antibody–drug conjugates: targeted drug delivery for cancer
Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 656
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Tai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Self-citationMimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., et al. (2012) · Blood · doi:10.1182/blood-2011-07-366633 · Cited by 432
Self-citation
Metadata
- Authors
- Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., Tai, Y.-T., Cirstea, D., Raje, N. S., Uherek, C., Dälken, B., Aigner, S., Osterroth, F., Munshi, N., Richardson, P., & Anderson, K. C.
- Venue
- Clinical Cancer Research
- Published
- 2009-06-15
- Volume
- 15
- Issue
- 12
- Pages
- 4028-4037
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2131340972
- Cited by
- 203
- References
- 3
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-2867
- The paper
- Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., Tai, Y.-T., Cirstea, D., Raje, N. S., Uherek, C., Dälken, B., Aigner, S., Osterroth, F., Munshi, N., . . . Anderson, K. C. (2009). The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-2867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.